Pharmacokinetic characterization of favipiravir in patients with COVID-19
Pharmacokinetic characterization of favipiravir in patients with COVID-19
Tarih
2022-01-01
Yazarlar
Gulhan, Rezzan
Eryuksel, Emel
Oglu, Medine Gulcebi Idriz
Culpan, Yekta
Toplu, Aylin
Kocakaya, Derya
Tigen, Elif
Sengel, Buket Erturk
Sili, Uluhan
Yildizeli, Sehnaz Olgun
Süreli Yayın başlığı
Süreli Yayın ISSN
Cilt Başlığı
Yayınevi
WILEY
Dergi Adı
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Özet
This prospective observational study describes the pharmacokinetic characteristics of favipiravir in adult patients hospitalized for mild to moderate COVID-19 with a positive RT-PCR test. Favipiravir was administered for 5 days, with a loading dose of 3200 mg and a maintenance dose of 1200 mg/day. Serial blood samples were collected on Day 2 and Day 4 of the therapy. Laboratory findings of the patients (n = 21) and in-hospital mortality were recorded. Favipiravir concentrations exhibited substantial variability and a significant decrease during the treatment of COVID-19. The median favipiravir trough concentration (C0-trough) on Day 2 was 21.26 (interquartile range {[}IQR], 8.37-30.78) mu g/mL, whereas it decreased significantly to 1.61 (IQR, 0.00-6.41) mu g/mL on Day 4, the area under the concentration-time curve decreased by 68.5\%. Day 2 C0-trough of female patients was higher than male patients. Our findings indicate that favipiravir concentrations show significant variability during the treatment of COVID-19 and therapeutic drug monitoring may be necessary to maintain targeted concentrations.
Açıklama
Anahtar kelimeler
COVID, favipiravir, pharmacokinetics, therapeutic drug monitoring